OTCMKTS:PFSCF - ProMetic Life Sciences Stock Price Target and Predictions

  • Consensus Rating: N/A
  • Consensus Price Target: $0.00
  • Forecasted Upside: -100.00 %
  • Number of Analysts: 0
  • Breakdown:
  • 0 Sell Ratings
  • 0 Hold Ratings
  • 0 Buy Ratings
  • 0 Strong Buy Ratings
$5.47
▼ -0.203 (-3.58%)
1 month | 3 months | 12 months
Get New ProMetic Life Sciences Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for PFSCF and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for PFSCF

i We calculate consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0-1.5 = Sell, 1.5-2.5 = Hold, 2.5-3.5 = Buy, >3.5 = Strong Buy). Our consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. Our consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.
$0.00
▼ -100.00% Downside Potential
This price target is based on 0 analysts offering 12 month price targets for ProMetic Life Sciences in the last 3 months. The average price target is $0.00, with a high forecast of $0.00 and a low forecast of $10,000,000.00. The average price target represents a -100.00% upside from the last price of $5.47.
N/A
The current consensus among 0 contributing investment analysts is to n/a stock in ProMetic Life Sciences. This rating has held steady since May 2020, when it changed from a Hold consensus rating.

Past Monthly Recommendations

Move your mouse over past months for details

  • 0 strong buy ratings
  • 0 buy ratings
  • 2 hold ratings
  • 0 sell ratings
10/29/2019
  • 0 strong buy ratings
  • 0 buy ratings
  • 2 hold ratings
  • 0 sell ratings
1/27/2020
  • 0 strong buy ratings
  • 0 buy ratings
  • 1 hold ratings
  • 0 sell ratings
4/26/2020
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
7/25/2020
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
10/23/2020
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
1/21/2021
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
3/22/2021
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
4/21/2021

Latest Recommendations

  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings

DateBrokerageActionRatingPrice TargetDetails
6/5/2019Royal Bank of CanadaDowngradeHold
i
Rating by Douglas Miehm at Royal Bank of Canada
4/23/2019Canaccord GenuityDowngradeHold
i
Rating by Dewey Steadman at Canaccord Genuity
4/5/2019Canaccord GenuityReiterated RatingBuy
i
Rating by Dewey Steadman at Canaccord Genuity
11/2/2017Cantor FitzgeraldInitiated CoverageOverweight
i
(Data available from 4/21/2016 forward)
ProMetic Life Sciences logo
Prometic Life Sciences Inc. operates as a biopharmaceutical company with two drug discovery platforms that focuses on unmet medical needs in the field of fibrosis and orphan diseases. Its product pipeline includes PBI-4050, an orally active lead drug candidate for fibrosis; plasminogen, a biopharmaceutical for the treatment of congenital plasminogen deficiency; and intravenous immunoglobulin, a preparation of antibodies purified from plasma donations from healthy individuals. The company was founded in 1992 and is based in Laval, Canada.
Read More

Today's Range

Now: $5.47
$5.47
$5.47

50 Day Range

MA: $5.47
$5.47
$5.47

52 Week Range

Now: $5.47
$5.47
$352.00

Volume

200 shs

Average Volume

279 shs

Market Capitalization

$127.45 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

2.46

Frequently Asked Questions

What sell-side analysts currently cover shares of ProMetic Life Sciences?

The following sell-side analysts have issued stock ratings on ProMetic Life Sciences in the last year:
View the latest analyst ratings for PFSCF.

What is the current price target for ProMetic Life Sciences?

0 Wall Street analysts have set twelve-month price targets for ProMetic Life Sciences in the last year. has the lowest price target set, forecasting a price of $10,000,000.00 for ProMetic Life Sciences in the next year.
View the latest price targets for PFSCF.

What is the current consensus analyst rating for ProMetic Life Sciences?

ProMetic Life Sciences currently has from Wall Street analysts. The stock has a consensus analyst rating of "N/A."
View the latest ratings for PFSCF.

What other companies compete with ProMetic Life Sciences?

How do I contact ProMetic Life Sciences' investor relations team?

ProMetic Life Sciences' physical mailing address is 440 Boulevard Armand-Frappier Suite 300, Laval A8, H7V 4B4. The company's listed phone number is 1-450-781-0115 and its investor relations email address is [email protected] The official website for ProMetic Life Sciences is www.prometic.com.